Katsuya
Lv3
240 积分
2024-01-12 加入
-
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
1天前
已完结
-
AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis
6天前
已完结
-
AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis
6天前
已完结
-
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
6天前
已完结
-
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist
12天前
已完结
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
15天前
已完结
-
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
15天前
已完结
-
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
16天前
已完结
-
Tirzepatide adds hepatoprotection to its armoury
16天前
已完结
-
Temporal trend and attributable risk factors of stroke burden in China, 1990–2019: an analysis for the Global Burden of Disease Study 2019
1个月前
已完结